## TOTAL SYNTHESIS OF ( - )-HALICHOLACTONE

Taichi Takahashi, Hidenori Watanabe, and Takeshi Kitahara\*

Department of Applied Biological Chemistry, Graduate School of Agriculturaland Life Sciences, The University of Tokyo, 1-1-1 Yayoi Bunkyo-ku, Tokyo, 113-8657, Japan

Abstract - A convergent total synthesis of halicholactone (1), 5-lipoxygenase inhibitor, using (1*S*, 5*S*, 6*R*)-5-hydroxybicyclo[4.1.0]-heptan-2-one (7) as a chiral building block is described. *Z*-Selective RCM reaction was the key step to construct the nine-membered unsaturated lactone linkage of 1.

Halicholactone (1) was isolated from the marine sponge, *Halichondoria okadai*, by Yamada *et al.* in 1989 along with neohalicholactone (2).<sup>1</sup> Halicholactone (1) exhibited inhibitory activity against 5-lipoxygenase of guinea pig polymorphonuclear leukocytes (IC<sub>50</sub>=630 μM). These compounds possess a *trans*-disubstituted cyclopropane ring and unsaturated lactone and comprise a linear C<sub>20</sub> carbon skeleton characteristic of oxylipin.<sup>2</sup> Therefore, it is believed that halicholactone (1) and neohalicholactone (2) are biosynthesized from arachidonic acid and eicosapentaenoic acid, respectively, *via* lipoxygenation and formation of lactone.<sup>3</sup> These biologically important and unique structural features have inspired several synthetic studies,<sup>4</sup> and Wills *et al.* have reported the first total synthesis<sup>5</sup> followed by several syntheses of 1.<sup>6</sup> We show here a novel approach to 1 using our chiral building block, (1*S*, 5*S*, 6*R*)-5-hydroxybicyclo[4.1.0]heptan-2-one (7).<sup>7,8</sup> We have reported the syntheses of natural products, sporogen-AO 1, phomenone,<sup>8</sup> gigantenone, phaseolinone<sup>9</sup>, and pironetine<sup>10</sup> and dendryphiellin C<sup>11</sup> using this building block (7) to date.

 $X = -CH_2CH_2$ - : Halicholactone (1) X = cis-CH=CH- : Neohalicholactone (2)

Figure 1.


Our synthetic strategy is illustrated in Scheme 1. As we decided to synthesize a nine-membered unsaturated lactone linkage of 1 using a Z-selective RCM reaction, 12 a terminal bisolefin (3) was employed as a precursor. This compound would be prepared from 4 by change of the protective groups, entailing esterification with 5-hexenoic acid. The compound (4) could be constructed from aldehyde (6) by the Nozaki-Hiyama-Kishi reaction (NHK reaction) with vinyl iodide (5), which is obtainable from (R)-1-octyn-3-ol. trans-Cyclopropyl aldehyde (6) should be synthesized from the key building block (7) via oxidative ring-cleavage of the corresponding silyl enol ether.

**Scheme 1.** Synthetic strategy of halicholactone

The ketol (7) was converted to protected silyl enol ether (8) by treatment with 2.3 equiv. of triisopropylsilyl triflate and triethylamine. Ozonolysis of 8, followed by the Wittig olefination gave carboxylic acid (9) in good yield. In order to obtain the requisite trans-cyclopropyl aldehyde (6), we prepared the corresponding cis-cycropropyl aldehyde (11) from 9, and examined isomerization to tras-derivative under basic conditions. Unfortunately, this attempt failed and gave a complex mixture. Therefore, we tried epimerization under Ohfune's condition<sup>14</sup> or several basic conditions using a methyl ester (10). When potassium *tert*-butoxide was employed as a base in DMSO at room temperature, a rather satisfactory result was obtained, giving 28% of trans-fused carboxylic acid (14) along with 28% of 9. This condition gave rise to hydrolyzate. To prevent this, we transformed the carboxylic acid (9) to t-butyl ester (12) using tert-butyl trichloroacetimidate and examined isomerization of more bulky t-butyl ester (12) than the methyl ester (10). The best yield was obtained by using a mixture of potassium tert-butoxide as a base, 18-crown-6 ether and molecular sieves 4 Å in benzene at 80°C to give the desired trans-cyclopropyl t-butyl ester (13) in 49% yielde and trans-carboxylic acid (14) in 28% yielde. The carboxylic acid (14) was converted to tert-butyl ester (14) using the same conditions as above. Reduction of 13 with LiAlH<sub>4</sub> followed by TPAP oxidation gave aldehyde (6) in 91% yield.

Scheme 2. Reagents and conditions: (a) TIPSOTf, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, 0°C (98%); (b) O<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, -78°C then PPh<sub>3</sub>; (c) Ph<sub>3</sub>PMeBr, n-BuLi, DME, 0°C (2 steps 71%); (d) CH<sub>2</sub>N<sub>2</sub>, Et<sub>2</sub>O, 0°C $\rightarrow$ rt (10, 99%); (e) CCl<sub>3</sub>C(=NH)Ot-Bu, BF<sub>3</sub>·OEt<sub>2</sub>, Cyclohexane (12, 96%); (f) LiAlH<sub>4</sub>, THF, 0°C (99%) then TPAP, NMO, CH<sub>2</sub>Cl<sub>2</sub>, rt (87%); (g) t-BuOK, 18-Crown-6-ether, MS 4Å, Benzene, reflux, for 12; (h) CCl<sub>3</sub>C(=NH)Ot-Bu, BF<sub>3</sub>·OEt<sub>2</sub>, Cyclohexane, rt (92%); (i) LiAlH<sub>4</sub>, THF, 65°C (99%); (h) TPAP, NMO, CH<sub>2</sub>Cl<sub>2</sub>, rt (92%).

Next, we synthesized vinyl iodide (5) from commercially available (R)-1-octyn-3-ol (15) to reaction. Protection examine NHK of 15 with TBSCl and hydrozirconation-iodination according to Schwartz's method gave vinyl iodide (16). 15 Deprotection of the TBS ether followed by acetylation gave the requisite vinyl iodide (5). The aldehyde (6) and the vinyl iodide (5) were treated with 5 wt % of NiCl<sub>2</sub> and CrCl<sub>2</sub> in 1:1 mixture of DMSO/DMF at room temperature to give the desired allylic alcohol (4) as a 2.5:1 mixture of diastereomers in 90% yield. The mixture was cleanly separated by silica gel chromatography and the stereochemistry of major product (4a) was confirmed by modified Mosher's method<sup>16</sup> and found to be the desired (R)-isomer (**Scheme 3**).



Scheme 3. Reagents and conditions: (a) TBSCl, imidazole, DMF, 0°C $\rightarrow$ rt (92%); (b) Cp<sub>2</sub>ZrHCl then I<sub>2</sub>, THF, rt (72%); (c) TBAF, THF, 0°C $\rightarrow$ rt (83%); (d) Ac<sub>2</sub>O, Et<sub>3</sub>N, DMAP, CH<sub>2</sub>Cl<sub>2</sub>, rt (99%); (e) **6**, CrCl<sub>2</sub>, NiCl<sub>2</sub> (0.5 wt%), DMF-DMSO(1:1), rt (**4a**: **4b** = 64%: 26%).

Initial protection of the secondary hydroxyl group of **4a** as acetate and subsequent removal of the triisopropylsilyl group using TBAF-HF gave **17** in 88% yield, which was converted to **3** by esterification with 5-hexenoic acid. RCM reaction of **3** with Grubbs' reagent<sup>17</sup> in the presence of a catalytic amount of Ti(O-*i*-Pr)<sub>4</sub>, reported by Takemoto,<sup>6b, 6c</sup> gave *Z*-olefin,<sup>12a</sup> nine-membered lactone derivative, in 93% yield along with 3% of a dimer. Finally, methanolysis of two acetates afforded halicholactone (**1**), the <sup>1</sup>H and <sup>13</sup>C NMR, IR, MS spectra and specific optical rotation of which were identical with those of the authentic sumple.<sup>18</sup>

**Scheme 4.** Reagents and conditions: (a) Ac<sub>2</sub>O, Et<sub>3</sub>N, DMAP, CH<sub>2</sub>Cl<sub>2</sub>, rt; (b) TBAF-HF, aq. THF, rt (2 steps 88%); (c) 5-Hexenoic acid, DCC, DMAP, CH<sub>2</sub>Cl<sub>2</sub>, rt (95%); (d) (Cy<sub>3</sub>P)<sub>2</sub>RuCl<sub>2</sub>=CHPh, Ti(O*i*-Pr)<sub>4</sub>, CH<sub>2</sub>Cl<sub>2</sub>, 40°C, 0.1 mM (93%); (e) K<sub>2</sub>CO<sub>3</sub>, MeOH, rt (55%).

In conclusion, we have succeeded in total synthesis of halicholactone *via* a convergent route in overall 12.5% yield through 14 steps from 7. This method is applicable to the synthesis of similar oxylipins, and our chiral building block (7) was again proved to be extremely versatile for the synthesis of bioactive natural products.

## ACKNOWLEDGEMENTS

The authors thanks Professor Y. Takemoto, University of Kyoto, for a kind gift of <sup>1</sup>H and <sup>13</sup>C-NMR spectra of halicholactone. This work was supported by a Grant-in-Aid for Scientific Research from the Japanese Ministry of Education, Culture, Sports, Science, and Technology.

## REFERENCES AND NOTES

1. (a) H. Niwa, K. Wakamatsu, and K. Yamada, *Tetrahedron Lett.*, 1989, **30**, 4543. (b) H. Kigoshi, H. Niwa, K. Yamada, T. J. Stouk, and J. Clardy, *Tetrahedron Lett.*, 1991, **32**, 2427.

- **2.** (a) W. H. Gerwick, *Chem. Rev.*, 1993, **93**, 1807. (b) W. H. Gerwick, *Biochim. Biophys. Acta*, 1994, **1211**, 243.
- 3. P. J. Proteau, J. V. Rossi, and W. H. Gerwick, J. Nat. Prod., 1994, 57, 1717.
- **4.** (a) J. D. White and M. S. Jensen, Synlett, 1996, **1**, 31.
- (a) D. J. Critcher, S. Connolly, and M. Wills, J. Chem. Soc., Chem. Commun., 1995, 139.
   (b) D. J. Critcher, S. Connolly, and M. Wills, Tetrahedron Lett., 1995, 36, 3763.
   (c) D. J. Critcher, S. Connolly, and M. Wills, J. Org. Chem., 1997, 62, 6638.
- 6. (a) A. Datta and D. K. Mohapatra, J. Org. Chem., 1998, 63, 642. (b) Y. Takemoto, Y. Baba, G. Saha, S. Nakao, C. Iwata, T. Tanaka, and T. Ibuka, Tetrahedron Lett., 2000, 41, 3653.
  (c) Y. Baba, G. Saha, S. Nakao, C. Iwata, T. Tanaka, T. Ibuka, H, Ohishi, and Y. Takemoto, J. Org. Chem., 2001, 66, 81.
- 7. T. Kitahara and K. Mori, Tetrahedron Lett., 1985, 26, 451.
- 8. T. Kitahara, H. Kurata, and K. Mori, *Tetrahedron*, 1988, **44**, 4339.
- 9. T. Kitahara, H. Kiyota, H. Kurata, and K. Mori, Tetrahedron, 1991, 47, 1649.
- 10.H. Watanabe, H. Watanabe, and T. Kitahara, Tetrahedron Lett., 1998, 39, 8313.
- 11. H. Akao, and H. Kiyota, T. Nakajima, and T. Kitahara, Tetrahedron, 1999, 55, 7757.
- For recent reference of RCM reaction: (a) A. Fürstner and K. Langemann, J. Am. Chem. Soc., 1997, 119, 9130. (b) M. E. Maier, Angew. Chem., Int. Ed., 2000, 39, 2073. (c) A, K. Chatterjee, J. P. Morgan, M. Scholl, and R. H. Grubss, J. Am. Chem. Soc., 2000, 122, 3783. (d) J. S. Clark and O. Hamelin, Angew. Chem., Int. Ed., 2000, 39, 372. (e) D. J. Holt, W. D. Barker, P. R. Jenkins, J. Panda, and S. Ghosh, J. Org. Chem., 2000, 65, 482. (f) A. Fürstner, O. R. Thiel, L. Ackermann, H. J. Schanz, and S. P. Nolan, J. Org. Chem., 2000, 65, 2204.
- (a) K. Takai, K. Kimura, T. Kuroda, T. Hiyama, and H. Nozaki, *Tetrahedron Lett.*, 1983,
   5281. (b) Y. Okude, S. Hirano, T. Hiyama, and H. Nozaki, *J. Am. Chem. Soc.*, 1977, 99, 3179. (c) H. Jin, J. Uenishi, W. J. Christ, and Y. Kishi, *J. Am. Chem. Soc.*, 1986, 108, 5644. (d) K. Takai, M. Tagashira, T. Kuroda, T. Oshima, K. Uthimoto, and H. Nozaki, *J. Am. Chem. Soc.*, 1986, 108, 6048.
- 14.(a) K. Shimamoto and Y. Ohfune, *Synlett*, 1993, 919. (b) Y. Ohfune, K. Shimamoto, M. Ishida, and H. Shinozaki, *Bioorg. Med. Chem. Lett.*, 1993, 3, 15.
- 15.D. W. Hart, T. F. Blackburn, and J. Schwartz, J. Am. Chem. Soc., 1975, 97, 679.
- (a) J. A. Dale and H. S. Mosher, J. Am. Chem. Soc., 1973, 95, 512.
   (b) I. Ohtani, T. Kushumi, Y. Kashman and H. Kakisawa, J. Am. Chem. Soc., 1991, 113, 4092.
- 17.(a) G. C. Fu and R. H. Grubbs, J. Am. Chem. Soc., 1992, 114, 5426. (b) G. C. Fu and R. H. Grubbs, J. Am. Chem. Soc., 1992, 114, 7324. (c) R. H. Grubbs, J. S. Miller, and G. C. Fu, Acc. Chem. Res., 1995, 28, 446.
- 18. Data for synthetic compound (1):  $[\alpha]_{D^{25}}$  -85.4° (c = 0.24, CHCl<sub>3</sub>); <sup>1</sup>H NMR (500 MHz, C<sub>6</sub>D<sub>6</sub>):  $\delta$  (ppm) 0.27 (1H, ddd, J = 5.0, 5.0, 8.0 Hz), 0.45 (1H, ddd, J = 4.0, 5.0, 9.0 Hz), 0.86 (1H, m), 0.88 (3H, t, J = 7.5 Hz), 1.05 (1H, m), 1.19-1.45 (6H, m), 1.49 (2H, m), 1.54

(2H, m), 1.74 (1H, m), 1.90 (1H, ddd, J = 1.5, 6.0, 13.0 Hz), 2.08 (2H, m), 2.34 (1H, m), 2.37 (1H, m), 3.55 (1H, dd, J = 4.0, 7.0 Hz), 3.94 (1H, m), 4.33 (1H, ddd, J = 1.5, 8.5, 12.0)Hz), 5.34-5.44(2H, m), 5.66-5.73 (2H, m); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ (ppm) 8.2 (CH<sub>2</sub>), 14.0 (CH<sub>3</sub>), 19.4 (CH), 22.6 (CH<sub>2</sub>), 23.4 (CH), 25.0 (CH<sub>2</sub>), 25.2 (CH<sub>2</sub>), 26.4 (CH<sub>2</sub>), 31.7 (CH<sub>2</sub>), 33.5 (CH<sub>2</sub>), 33.8 (CH<sub>2</sub>), 37.2 (CH<sub>2</sub>), 72.3 (CH), 74.1 (CH), 76.1 (CH), 124.6 (CH), 131.6 (CH), 134.0 (CH), 134.6 (CH), 174.1 (C); IR (film) v<sub>max</sub>: 3424, 2927, 1738 cm<sup>-1</sup>; HRMS (FAB) Calcd for  $C_{20}H_{31}O_3$  (M-OH): 319.2273. Found: 319.2278. [ lit.,  $^{1a}$  [ $\alpha$ ] $_D^{23}$  -85.4°  $(c = 1.16, CHCl_3)$ ; <sup>1</sup>H NMR (500 MHz,  $C_6D_6$ ):  $\delta$  (ppm) 0.29 (1H, ddd, J = 5.0, 5.0, 8.0 Hz), 0.47 (1H, ddd, J = 5.0, 5.0, 8.0 Hz), 0.86 (1H, m), 0.89 (3H, t, J = 7.0 Hz), 1.03 (1H, m), 1.10-1.40 (6H, m), 1.50 (2H, m), 1.55 (2H, m), 1.77 (1H, m), 1.91 (1H, ddd, J = 1.5, 7.0, 13.0 Hz), 2.07 (2H, m), 2.34 (1H, m), 2.37 (1H, m), 3.53 (1H, dd, J = 4.0, 7.0 Hz), 3.92 (1H, m), 4.32 (1H, ddd, J = 1.5, 8.0, 12.0 Hz), 5.35-5.45(2H, m), 5.65-5.73 (2H, m); 13C NMR (300 MHz, CDCl3): δ (ppm) 8.2 (CH<sub>2</sub>), 14.0 (CH<sub>3</sub>), 19.5 (CH), 22.6 (CH<sub>2</sub>), 23.5 (CH), 25.1 (CH<sub>2</sub>), 25.3 (CH<sub>2</sub>), 26.5 (CH<sub>2</sub>), 31.8 (CH<sub>2</sub>), 33.6 (CH<sub>2</sub>), 33.9 (CH<sub>2</sub>), 37.3 (CH<sub>2</sub>), 72.3 (CH), 74.2 (CH), 76.1 (CH), 124.7 (CH), 131.7 (CH), 134.1 (CH), 134.7 (CH), 174.0 (C); IR (film)  $v_{\text{max}}$ : 3640, 3460, 1730 cm<sup>-1</sup>].